World's First Dual GCG/GLP-1 Receptor Agonist for Obesity Approved in China, Delivered via Ypsomed Autoinjector

Reuters

07/01

World's First Dual GCG/GLP-1 Receptor Agonist for Obesity Approved in China, Delivered via Ypsomed Autoinjector

Ypsomed Holding AG has announced the regulatory approval of Mazdutide, the world's first dual GCG/GLP-1 receptor agonist drug for the treatment of obesity, by the Chinese National Medical Products Administration (NMPA). This groundbreaking therapy, developed by Innovent Biologics, Inc., will be delivered using Ypsomed's YpsoMate 1.0 autoinjector. The approval marks a significant milestone in obesity treatment, emphasizing Ypsomed's strategic "China for China" approach aimed at strengthening supply chain resilience and ensuring proximity to the Chinese market. The collaboration between Ypsomed and Innovent Biologics has been established since 2019, highlighting both companies' commitment to innovation and accessible healthcare solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ypsomed Holding AG published the original content used to generate this news brief on July 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2548802921"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548802921\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548802921?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-01 13:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548802921","market":"fut","top_or_hot":-1,"title":"World's First Dual GCG/GLP-1 Receptor Agonist for Obesity Approved in China, Delivered via Ypsomed Autoinjector","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      World's First Dual GCG/GLP-1 Receptor Agonist for Obesity Approved in China, Delivered via Ypsomed Autoinjector\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/YPHDF\">Ypsomed Holding AG</a> has announced the regulatory approval of Mazdutide, the world's first dual GCG/GLP-1 receptor agonist drug for the treatment of obesity, by the Chinese National Medical Products Administration (NMPA). This groundbreaking therapy, developed by Innovent Biologics, Inc., will be delivered using Ypsomed's YpsoMate 1.0 autoinjector. The approval marks a significant milestone in obesity treatment, emphasizing Ypsomed's strategic \"China for China\" approach aimed at strengthening supply chain resilience and ensuring proximity to the Chinese market. The collaboration between Ypsomed and Innovent Biologics has been established since 2019, highlighting both companies' commitment to innovation and accessible healthcare solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ypsomed Holding AG published the original content used to generate this news brief on July 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>World's First Dual GCG/GLP-1 Receptor Agonist for Obesity Approved in China, Delivered via Ypsomed Autoinjector</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWorld's First Dual GCG/GLP-1 Receptor Agonist for Obesity Approved in China, Delivered via Ypsomed Autoinjector\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-01 13:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      World's First Dual GCG/GLP-1 Receptor Agonist for Obesity Approved in China, Delivered via Ypsomed Autoinjector\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/YPHDF\">Ypsomed Holding AG</a> has announced the regulatory approval of Mazdutide, the world's first dual GCG/GLP-1 receptor agonist drug for the treatment of obesity, by the Chinese National Medical Products Administration (NMPA). This groundbreaking therapy, developed by Innovent Biologics, Inc., will be delivered using Ypsomed's YpsoMate 1.0 autoinjector. The approval marks a significant milestone in obesity treatment, emphasizing Ypsomed's strategic \"China for China\" approach aimed at strengthening supply chain resilience and ensuring proximity to the Chinese market. The collaboration between Ypsomed and Innovent Biologics has been established since 2019, highlighting both companies' commitment to innovation and accessible healthcare solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ypsomed Holding AG published the original content used to generate this news brief on July 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL4r1Hn1:1","article_id":"2548802921","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548802921","pubTimestamp":1751346207,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ypsomed Holding AG has announced the regulatory approval of Mazdutide, the world's first dual GCG/GLP-1 receptor agonist drug for the treatment of obesity, by the Chinese National Medical Products Administration . This groundbreaking therapy, developed by Innovent Biologics, Inc., will be delivered using Ypsomed's YpsoMate 1.0 autoinjector. The approval marks a significant milestone in obesity treatment, emphasizing Ypsomed's strategic \"China for China\" approach aimed at strengthening supply chain resilience and ensuring proximity to the Chinese market. The collaboration between Ypsomed and Innovent Biologics has been established since 2019, highlighting both companies' commitment to innovation and accessible healthcare solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念","01911":"华兴资本控股","01801":"信达生物","BK1589":"北水核心资产","BK1147":"投资银行业与经纪业","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"全球首个用于肥胖的GCG/GLP-1双重受体激动剂在中国获批，通过Ypsomed自动注射器递送","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9,"01911":0.9},"content_text":"World's First Dual GCG/GLP-1 Receptor Agonist for Obesity Approved in China, Delivered via Ypsomed Autoinjector\n    \n\nYpsomed Holding AG has announced the regulatory approval of Mazdutide, the world's first dual GCG/GLP-1 receptor agonist drug for the treatment of obesity, by the Chinese National Medical Products Administration (NMPA). This groundbreaking therapy, developed by Innovent Biologics, Inc., will be delivered using Ypsomed's YpsoMate 1.0 autoinjector. The approval marks a significant milestone in obesity treatment, emphasizing Ypsomed's strategic \"China for China\" approach aimed at strengthening supply chain resilience and ensuring proximity to the Chinese market. The collaboration between Ypsomed and Innovent Biologics has been established since 2019, highlighting both companies' commitment to innovation and accessible healthcare solutions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ypsomed Holding AG published the original content used to generate this news brief on July 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}